News >

Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer

Danielle Bucco
Published: Thursday, Dec 28, 2017

Erika P. Hamilton, MD

Erika P. Hamilton, MD
Patients with HER2-positive breast cancer no longer have as poor of a prognosis due to the development of numerous HER2-directed therapies, explains Erika P. Hamilton, MD.

, Hamilton, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discussed recent FDA approvals in the treatment paradigm of HER2-positive breast cancer and shed light on the prevalence of brain metastases.

OncLive: If a patient undergoes testing and it comes back that they have HER2 expression, what are some of the first things you are thinking about when determining treatment?

Hamilton: We know that HER2-positive breast cancers are more aggressive and tend to grow quicker. However, we now have HER2-directed therapies that make this disease not as poor of a prognosis as it used to be. In many ways, we all dread triple-negative breast cancer much more than HER2-positive breast cancer now, with the advent of improved HER2-targeted agents that have improved outcomes significantly. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication